Immunotherapy Alone Can Successfully Treat Some Cancers: The Breakthrough of dMMR/MSI-H Tumors

Updated: August 2026

For decades, cancer treatment followed a familiar pattern: diagnose the tumor, remove it with surgery if possible, and add chemotherapy or radiation to destroy remaining cancer cells.

A new era of precision oncology is challenging this approach. In a subset of cancers with specific genetic features, immunotherapy alone has produced remarkable results — with some patients achieving complete tumor disappearance while avoiding traditional treatments that can affect quality of life.

The breakthrough centers around tumors with deficient mismatch repair (dMMR) and/or microsatellite instability-high (MSI-H) characteristics. These tumors accumulate large numbers of genetic mutations, creating abnormal proteins that make them highly visible to the immune system.

Clinical research from Memorial Sloan Kettering Cancer Center (MSKCC) and other leading oncology institutions has demonstrated that immune checkpoint inhibitors, particularly PD-1 blocking therapies such as dostarlimab, can produce deep and durable responses in selected patients.

Key Takeaways

• dMMR/MSI-H tumors are genetically unstable cancers that often contain many mutations recognizable by the immune system.
• PD-1 checkpoint inhibitors can reactivate immune cells and allow the body's own defenses to attack cancer.
• Some patients with dMMR cancers have achieved complete clinical responses using immunotherapy without immediate surgery, chemotherapy, or radiation.
• The success of immunotherapy depends heavily on biomarkers such as MMR status, MSI status, tumor mutation burden, and immune microenvironment characteristics.
• This represents a shift from treating cancer only by location (colon cancer, rectal cancer, gastric cancer) toward treating cancer based on molecular biology.

What Is dMMR Cancer?

DNA damage occurs constantly inside human cells. Normally, specialized repair systems identify and correct these errors before they accumulate.

One of the most important repair systems is called the mismatch repair (MMR) pathway.

The MMR system involves several key proteins:

• MLH1
• MSH2
• MSH6
• PMS2

When these repair mechanisms fail, the tumor becomes mismatch repair deficient (dMMR or MMRd).

Without effective DNA repair, cancer cells accumulate thousands of mutations. These mutations create abnormal proteins called neoantigens, which can act like biological warning signals recognized by immune cells.

What Is MSI-H?

Microsatellites are short repeated sequences of DNA scattered throughout the human genome.

In normal cells, mismatch repair proteins maintain the accuracy of these sequences. However, when the repair system fails, microsatellite regions become unstable.

This condition is called:

• Microsatellite instability-high (MSI-H)

MSI-H and dMMR are closely related biomarkers and often describe the same biological phenomenon from different testing perspectives.

Approximately:

• 15% of colorectal cancers are MSI-H/dMMR
• A subset of gastric, endometrial, ovarian, pancreatic, prostate, and other cancers may also carry this feature

Why Are dMMR/MSI-H Tumors More Sensitive to Immunotherapy?

Cancer cells normally develop mechanisms to hide from the immune system. One important pathway involves the interaction between PD-1 receptors on immune cells and PD-L1 proteins expressed by tumor cells.

This interaction acts like an immune "brake."

When PD-1 binds to PD-L1, immune cells receive signals telling them:

"Do not attack this cell."

Checkpoint inhibitors remove this brake.

PD-1 inhibitors, including dostarlimab and other checkpoint therapies, block this immune escape pathway, allowing T cells to recognize and destroy cancer cells.

How PD-1 Immunotherapy Works

The immune system contains specialized cells called T lymphocytes that can identify abnormal cells.

However, cancer evolves multiple strategies to suppress immune attacks.

Checkpoint inhibitors work by:

1. Blocking inhibitory signals between cancer cells and immune cells.
2. Restoring T-cell activity against tumor cells.
3. Allowing immune memory to develop against cancer-associated targets.

Unlike chemotherapy, which directly kills rapidly dividing cells, immunotherapy trains the immune system to recognize cancer as a threat.

The Importance of Precision Oncology

Traditional oncology classified cancers mainly according to their anatomical location:

• Colon cancer
• Lung cancer
• Breast cancer
• Rectal cancer

Modern precision oncology increasingly classifies cancers according to molecular characteristics:

• dMMR/MSI-H status
• PD-L1 expression
• Tumor mutation burden (TMB)
• Specific genetic mutations
• Immune microenvironment

This approach allows patients with completely different cancer types but the same biological weakness to receive similar targeted therapies.

A New Era: From Tumor Removal to Immune Control

The emergence of immunotherapy-only treatment strategies represents a major philosophical change in oncology.

Instead of asking:

"Where is the cancer located?"

Modern oncology increasingly asks:

"What makes this cancer vulnerable?"

For patients with dMMR/MSI-H tumors, the answer may be immune activation — transforming cancer from a disease requiring aggressive physical removal into one that can potentially be controlled by the patient's own immune system.

The MSKCC Breakthrough: Immunotherapy Alone Achieves Complete Responses in dMMR Cancers

One of the most important developments in modern oncology has been the demonstration that some cancers can be effectively controlled using immunotherapy alone, without immediate surgery, chemotherapy, or radiation.

Researchers at Memorial Sloan Kettering Cancer Center (MSKCC) investigated whether a PD-1 immune checkpoint inhibitor could treat patients with locally advanced or metastatic solid tumors characterized by deficient mismatch repair (dMMR).

The findings changed expectations for what may be possible in precision cancer medicine: some patients experienced complete disappearance of detectable cancer while preserving normal organ function and avoiding the long-term complications associated with traditional treatments.

Dostarlimab: The PD-1 Checkpoint Inhibitor Behind the Breakthrough

Dostarlimab is a monoclonal antibody designed to block the programmed death-1 (PD-1) immune checkpoint pathway.

PD-1 is a regulatory protein found on T cells. Under normal conditions, it prevents excessive immune activation and protects healthy tissues from autoimmune damage.

However, many cancers exploit this pathway by activating PD-1 signaling to suppress immune attacks.

By blocking PD-1, dostarlimab allows T cells to:

• Recognize abnormal tumor cells
• Restore anti-cancer immune activity
• Expand immune responses against cancer-associated mutations
• Create longer-lasting immune surveillance

The Landmark Clinical Trial

The MSKCC research program evaluated patients whose tumors demonstrated:

• Mismatch repair deficiency (dMMR)
• Microsatellite instability-high (MSI-H) status
• Advanced solid tumors considered appropriate for immune checkpoint blockade

Patients received dostarlimab as the primary treatment approach rather than immediately proceeding with conventional local therapies.

The goal was not only tumor shrinkage but also determining whether immunotherapy could provide:

• Complete tumor elimination
• Long-term disease control
• Avoidance of surgery
• Preservation of quality of life

Complete Clinical Responses: When Cancer Becomes Undetectable

A complete clinical response means that available imaging, endoscopy, biopsies, and other evaluations show no detectable evidence of cancer.

In the MSKCC experience, many patients achieved complete responses after immunotherapy alone.

This outcome is particularly significant because conventional treatment for locally advanced cancers often involves combinations of:

• Surgery
• Chemotherapy
• Radiation therapy

Although these treatments can be highly effective, they may also cause permanent side effects.

Rectal Cancer: The First Major Proof of Concept

The most widely recognized example involved patients with locally advanced rectal cancer containing dMMR/MSI-H biomarkers.

Historically, treatment frequently required:

• Chemoradiation
• Total mesorectal excision surgery
• Permanent or temporary bowel function changes in some patients

The MSKCC investigators demonstrated that selected patients could achieve complete responses with PD-1 blockade alone.

Importantly, patients who achieved complete responses could enter an active surveillance approach instead of automatically undergoing surgery.

Organ Preservation: A New Goal in Cancer Treatment

Traditional oncology has focused primarily on survival.

Modern cancer care increasingly recognizes another critical outcome:

How well can patients live after treatment?

Organ preservation aims to eliminate cancer while maintaining normal function.

Avoiding unnecessary surgery may help preserve:

• Normal bowel function
• Urinary function
• Sexual function
• Body image
• Daily activities

This represents a major shift toward patient-centered oncology.

Avoiding Chemotherapy and Radiation Toxicity

Chemotherapy and radiation remain essential treatments for many cancers and have saved millions of lives.

However, they can produce significant short-term and long-term effects, including:

• Fatigue
• Nausea
• Neuropathy
• Immune suppression
• Infertility risks
• Organ-specific complications

For appropriately selected dMMR/MSI-H patients, successful immunotherapy may reduce or eliminate the need for some conventional treatments.

Quality of Life: Beyond Tumor Response

A major strength of immunotherapy-only strategies is that success is measured not only by cancer control but also by patient experience.

Important quality-of-life considerations include:

• Maintaining normal daily activities
• Avoiding permanent treatment-related disability
• Reducing psychological burden associated with aggressive treatment
• Preserving independence

This approach reflects a broader movement in oncology toward balancing survival with quality of life.

Why These Results Are Important for the Future of Cancer Care

The MSKCC findings demonstrate a fundamental principle of precision oncology:

The biology of a cancer may matter more than its location.

A colorectal tumor, gastric tumor, or endometrial tumor with dMMR/MSI-H characteristics may share the same vulnerability to immune checkpoint blockade.

This has accelerated the development of:

• Biomarker-driven clinical trials
• Tumor-agnostic therapies
• Molecular classification systems
• Personalized immunotherapy strategies

Important Limitations and Clinical Considerations

Although the results are remarkable, immunotherapy is not a universal cancer cure.

Important considerations include:

• Only a subset of cancers are dMMR/MSI-H.
• Not every patient responds to checkpoint inhibitors.
• Some cancers develop resistance after initial response.
• Immune-related side effects can occur.
• Long-term follow-up remains essential.

The future of oncology will likely involve combining biomarkers, imaging, artificial intelligence, and immune profiling to identify the patients most likely to benefit.

The Future: Cancer Treatment Without Traditional Toxicity?

The MSKCC experience represents a new direction in cancer medicine:

Destroy the cancer by activating the patient's own immune system while preserving normal life.

For patients with dMMR/MSI-H tumors, immunotherapy has moved from an experimental concept to a clinically meaningful treatment option.

The next generation of oncology will focus not only on extending survival but also on achieving cures with fewer side effects and better quality of life.

dMMR/MSI-H Immunotherapy Across Different Cancer Types

Although the first major success story involved rectal cancer, the importance of dMMR/MSI-H biology extends far beyond one tumor type.

Because mismatch repair deficiency creates a high mutation burden and increased production of tumor-specific antigens, multiple cancer types with this molecular signature may respond to immune checkpoint inhibitors.

This has contributed to the development of tumor-agnostic cancer therapies — treatments selected according to genetic characteristics rather than only the organ where the cancer originated.

Colorectal Cancer: The Largest dMMR Cancer Population

Colorectal cancer is one of the most extensively studied cancers in relation to mismatch repair deficiency.

Approximately 10–15% of colorectal cancers demonstrate MSI-H/dMMR characteristics.

These tumors are especially important because:

• They often contain many mutations.
• They generate immune-recognizable neoantigens.
• They may respond strongly to PD-1 checkpoint blockade.

For patients with metastatic MSI-H colorectal cancer, immune checkpoint inhibitors have become an important treatment option and have changed the standard treatment landscape.

Endometrial Cancer

Endometrial cancer has one of the highest frequencies of dMMR/MSI-H alterations among common solid tumors.

Mismatch repair deficiency may occur through:

• Inherited mutations associated with Lynch syndrome.
• Acquired loss of MMR protein expression during tumor development.

Because these tumors often have increased immune activity, checkpoint inhibitors have demonstrated meaningful clinical benefit in selected patients.

Gastric and Gastroesophageal Cancers

A subset of gastric and gastroesophageal cancers are MSI-H/dMMR.

These tumors may have:

• Higher mutation rates
• Increased immune cell infiltration
• Greater sensitivity to immune checkpoint blockade

Testing for MSI/MMR status has therefore become an important component of modern gastric cancer evaluation.

Other Solid Tumors Associated With dMMR/MSI-H

Mismatch repair deficiency can also occur in several additional cancers, including:

• Small bowel cancers
• Pancreatic cancers (a smaller subset)
• Ovarian cancers
• Urothelial cancers
• Prostate cancers (rare subsets)
• Brain tumors and other uncommon malignancies

The frequency varies significantly depending on cancer type, stage, and population studied.

Biomarker Testing: How Doctors Identify Patients Who May Benefit

Successful immunotherapy depends on identifying the biological features that make a tumor vulnerable.

Several complementary tests are used in clinical practice.

1. Immunohistochemistry (IHC) for MMR Proteins

Immunohistochemistry evaluates whether tumor cells express the major mismatch repair proteins:

• MLH1
• MSH2
• MSH6
• PMS2

Loss of one or more proteins suggests mismatch repair deficiency.

2. Microsatellite Instability Testing

MSI testing evaluates changes in repetitive DNA sequences.

Results are generally classified as:

• MSI-H: High microsatellite instability
• MSS: Microsatellite stable
• MSI-L: Low microsatellite instability

MSI-H tumors are more likely to demonstrate strong responses to immune checkpoint inhibitors.

3. Tumor Mutation Burden (TMB)

Tumor mutation burden measures the number of DNA mutations present within a tumor genome.

A high mutation burden may indicate:

• More abnormal proteins produced by cancer cells.
• Greater immune system recognition.
• Potential sensitivity to immunotherapy.

However, TMB alone is not a perfect predictor and must be interpreted together with other biomarkers.

4. PD-L1 Expression

PD-L1 testing measures expression of the PD-L1 protein on tumor or immune cells.

High PD-L1 expression may indicate greater likelihood of response in some cancers, although the relationship varies by tumor type.

Universal MMR/MSI Testing: Why It Matters

Because dMMR/MSI-H status can influence treatment decisions and identify possible inherited cancer risk, many oncology organizations recommend routine testing in several cancers, especially colorectal and endometrial cancers.

Benefits of testing include:

• Identifying patients eligible for immunotherapy.
• Detecting possible Lynch syndrome.
• Helping family members understand inherited cancer risk.
• Guiding personalized treatment decisions.

Lynch Syndrome: The Inherited Connection

Some dMMR cancers occur because of inherited mutations affecting mismatch repair genes.

This condition is known as Lynch syndrome.

People with Lynch syndrome have increased risks of several cancers, including:

• Colorectal cancer
• Endometrial cancer
• Ovarian cancer
• Gastric cancer
• Other associated malignancies

Identifying Lynch syndrome can provide important information for patients and their families.

Why Immunotherapy Does Not Work for Everyone

Despite dramatic responses in some patients, checkpoint inhibitors are not universally effective.

Possible reasons include:

• Lack of sufficient tumor mutations.
• Immune suppression within the tumor microenvironment.
• Failure of immune cells to penetrate the tumor.
• Development of acquired resistance.
• Alternative immune escape pathways.

Immune-Related Side Effects

Unlike chemotherapy toxicity, immune checkpoint inhibitor side effects result from increased immune activation.

Potential immune-related adverse events include:

• Skin inflammation
• Thyroid disorders
• Colitis
• Hepatitis
• Pneumonitis
• Other autoimmune-like reactions

Most immune-related toxicities can be managed effectively when recognized early.

The Future of Biomarker-Driven Cancer Medicine

The success of dMMR/MSI-H immunotherapy demonstrates a broader transformation in oncology.

Future cancer treatment will increasingly integrate:

• Genomic sequencing
• Artificial intelligence cancer analysis
• Immune profiling
• Liquid biopsy technology
• Personalized treatment algorithms

The goal is to match every patient with the therapy most likely to work based on the unique biology of their cancer.

Key Message for Patients

A cancer diagnosis today is increasingly defined not only by where the cancer started, but by what makes the cancer biologically vulnerable.

For patients with dMMR/MSI-H tumors, immunotherapy has created possibilities that were unimaginable only a decade ago — including long-lasting responses, organ preservation, and improved quality of life.

Frequently Asked Questions (FAQ)

What is dMMR cancer?

dMMR (deficient mismatch repair) cancer is a tumor with defects in the DNA repair system. These defects cause cancer cells to accumulate many mutations, creating abnormal proteins that can make the tumor more visible to the immune system.

What is MSI-H cancer?

MSI-H (microsatellite instability-high) refers to tumors with significant instability in repetitive DNA sequences caused by impaired mismatch repair. MSI-H and dMMR are closely related biomarkers and often describe the same biological process.

Can immunotherapy cure cancer?

Immunotherapy has produced complete and durable responses in some patients, especially those with biomarkers such as dMMR/MSI-H. However, it is not a universal cure and effectiveness depends on cancer type, stage, molecular characteristics, and individual patient factors.

What immunotherapy drug was used in the MSKCC study?

The MSKCC research program investigated dostarlimab, a PD-1 immune checkpoint inhibitor designed to restore the immune system's ability to recognize and attack cancer cells.

Why do dMMR tumors respond better to immunotherapy?

dMMR tumors contain many genetic mutations. These mutations create abnormal proteins called neoantigens, which can help immune cells identify the cancer as abnormal and mount a stronger attack after checkpoint inhibition.

Does immunotherapy replace surgery and chemotherapy?

Not for all patients. Surgery, chemotherapy, and radiation remain essential treatments for many cancers. However, in carefully selected patients with highly responsive biomarkers, immunotherapy may reduce or eliminate the need for some traditional treatments.

Should every cancer patient get MSI or MMR testing?

Testing recommendations depend on cancer type and clinical situation. Many colorectal and endometrial cancer patients are routinely evaluated because MMR/MSI status can affect treatment decisions and identify possible inherited cancer syndromes.

What other biomarkers are important in immunotherapy?

Important biomarkers include:

• MSI status
• MMR protein expression
• PD-L1 expression
• Tumor mutation burden (TMB)
• Tumor immune microenvironment
• Specific genomic alterations

Conclusion: A New Chapter in Cancer Treatment

The success of immunotherapy in dMMR/MSI-H cancers represents one of the most important advances in modern oncology.

For decades, cancer therapy focused primarily on destroying tumors through surgery, radiation, and chemotherapy. Precision immunotherapy introduces a different strategy: activating the patient's own immune system to recognize and eliminate cancer.

The MSKCC experience with dostarlimab demonstrates that some cancers may be exceptionally vulnerable when their biological weaknesses are understood.

The future of oncology will likely not be defined by a single treatment approach, but by combining:

• Genomic testing
• Immune biomarkers
• Artificial intelligence
• Precision medicine
• Personalized treatment strategies

The ultimate goal is not only longer survival, but survival with preserved function, reduced toxicity, and improved quality of life.

References and Further Reading

1. Cercek A, et al. PD-1 Blockade in Mismatch Repair–Deficient, Locally Advanced Rectal Cancer. New England Journal of Medicine.
2. Memorial Sloan Kettering Cancer Center. Research updates on immunotherapy-only treatment strategies for dMMR cancers.
3. Le DT, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. New England Journal of Medicine.
4. National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology.
5. American Society of Clinical Oncology (ASCO) Clinical Practice Guidelines.